Trump announces trade deal with EU following months of negotiations
Cathie Wood’s ARK ETF published their daily trades for Tuesday, February 18th, 2025, showcasing a continued focus on the biotech sector. The largest trade of the day was the purchase of 60,227 shares of Twist Bioscience Corp (NASDAQ:TWST), amounting to a total dollar value of $2,866,202. This move signals ARK’s growing interest in the genomic sequencing company, as it follows a pattern of consistent buying, including a significant 82,632 shares added just the previous week.
In addition to Twist Bioscience, ARK also increased its stake in Beam Therapeutics Inc (NASDAQ:BEAM) by acquiring a combined 47,127 shares across its ARKK and ARKG ETFs, valued at $1,526,914. This trade continues a trend seen over the past week, with ARK previously buying 70,612 shares on Thursday and 19,16 shares on Friday, indicating a bullish outlook on the gene-editing company.
Another notable trade was the purchase of 9,021 shares of Ibotta Inc (NYSE:IBTA) through the ARKF ETF, with a total dollar value of $666,561. This follows a larger acquisition of the same stock on Friday, suggesting ARK’s increased confidence in the mobile technology company.
The consistency of ARK’s investments in these companies underscores a strategic emphasis on innovative and disruptive technologies, particularly within the biotech and genomics industries. Investors following Cathie Wood’s ARK ETFs are witnessing a clear pattern of investment that leans heavily towards companies poised for growth in these cutting-edge sectors.
While the focus remains on these larger trades, ARK’s daily report also reflects a series of smaller transactions that contribute to the overall investment strategy of the ETFs. As ARK continues to adjust its holdings, investors are provided with insights into the evolving landscape of technological advancements and the ETFs’ positions in companies leading these changes.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.